Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v2.4.0.8
Commitments and Contingencies - Additional Information (Detail) (USD $)
6 Months Ended
Jun. 30, 2014
UFRF License Agreements [Member]
 
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 5.00%
Company's obligation to pay from all revenue received from sublicenses 22.00%
One-time commercialization fee monthly amount for calculation $ 5,000
Post-commercialization minimum royalty payments 50,000
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount 2,000,000
One-time additional payment to UFRF as a percentage of total royalties due to UFRF 10.00%
Commercial sales 0
Commercialization fees 0
Minimum annual maintenance payment per license agreement 10,000
Aggregate minimum annual maintenance payment 20,000
Quarterly maintenance payment to UFRF under installment plan 5,000
Termination notice period 90 days
Texas A and M University License [Member]
 
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 5.00%
Initial payment to Texas A&M 5,000
Minimum consideration for the continuation of the license agreement 15,000
Minimum annual amount to Texas A&M 100,000
Annual maintenance payment under licensing agreement with Texas A&M 100,000
Maximum period to cure the breach 60 days
Termination notice period 90 days
Texas A and M University License [Member] | Phase I Clinical Trial [Member]
 
Commitment And Contingencies [Line Items]  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2015
Milestone payment under licensing agreement 50,000
Texas A and M University License [Member] | Phase II Clinical Trial [Member]
 
Commitment And Contingencies [Line Items]  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2019
Milestone payment under licensing agreement 100,000
Texas A and M University License [Member] | Phase III Clinical Trial [Member]
 
Commitment And Contingencies [Line Items]  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2022
Milestone payment under licensing agreement 150,000
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]
 
Commitment And Contingencies [Line Items]  
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2025
Milestone payment under licensing agreement 400,000
Texas A and M University License [Member] | Minimum [Member]
 
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 2.00%
Probiotics ECC [Member]
 
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 10.00%
Maximum period to cure the breach 60 days
Number of milestones achieved 0
Termination notice period 90 days
Milestone measurement period 30 days
Probiotics ECC [Member] | Phase II Clinical Trial [Member]
 
Commitment And Contingencies [Line Items]  
Milestone payment under licensing agreement 2,000,000
Probiotics ECC [Member] | Phase III Clinical Trial [Member]
 
Commitment And Contingencies [Line Items]  
Milestone payment under licensing agreement 5,000,000
Probiotics ECC [Member] | Sale Of Licensed Technology [Member]
 
Commitment And Contingencies [Line Items]  
Milestone payment under licensing agreement $ 10,000,000
Lantibiotic Exclusive Channel Collaboration (ECC) [Member]
 
Commitment And Contingencies [Line Items]  
Company's obligation to pay from percentage of selling price of product 25.00%
Company's obligation to pay from all revenue received from sublicenses 50.00%
Number of shares issued 4,392,425
Maximum percentage of primary investment securities to investment of shares issued 10.00%
Number of milestones achieved 0
Termination notice period 90 days
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Investigational New Drug Application [Member]
 
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 1.00%
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Clinical Study Phase 2 [Member]
 
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 1.50%
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Clinical Study Phase 3 [Member]
 
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 2.00%
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Filing of First Investigational New Drug Application [Member]
 
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 2.50%
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | First Regulatory Approval of Oragenics Product [Member]
 
Commitment And Contingencies [Line Items]  
Percentage of number of shares of common stock equal to Base Shares 3.00%